Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • About Shruti
  • Books
  • Insights
  • Operational Excellence
  • Research
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
  • Case Studies
  • Tools
    • Whitepapers
    • Articles >
      • Business Transformation
      • Process Improvement
      • Business Continuity
      • Change Management
      • Digital Transformation
      • Quality Improvement
    • Checklists and Templates
    • Free eBook
    • Videos
  • Blog
  • Engage Shruti
    • Consulting >
      • Operational Excellence Consulting
      • Business Transformation Consulting
      • Innovation Management Consulting
    • Workshops
  • Contact

FDA Approves Novel Asthma Treatment.

5/8/2010

0 Comments

 
Here are some highlights from current pharma and clinical research news, views and data.
 
FDA Approves Novel Asthma Treatment.  USFDA recently approved the "first non-drug asthma treatment- Alair." According to the developer the procedure known as "bronchial thermoplasty" would "only be appropriate for about two million adults with severe asthma who don't get relief from existing drugs."  

The device, delivers radiofrequency energy directly to the airways, heating and reducing the thickness of lung tissue and improving users' ability to breathe, the agency said in a news release. But, "to achieve the device's full benefit, users will require multiple sessions targeting different parts of the lungs." Notably, "as a condition of approval," the California-based manufacturer "must conduct additional studies to evaluate the product's long-term safety and effectiveness, the FDA said."  

The initial 297-patient study "found patients treated with Alair experienced an average 32% reduction in asthma attacks, 84% reduction in emergency" department "visits for respiratory symptoms, 73% reduction in respiratory-related symptoms, and 66% reduction in time absent from daily activities due to asthma,"  

Adverse effects of system treatment include asthma attacks, wheezing, chest tightness, chest pain, atelectasis, hemoptysis, anxiety, headaches, and nausea. Moreover, certain individuals should not use the device, and "those with an active respiratory infection, coagulopathy, asthma exacerbation, or change in corticosteroid regimen within 14 days of intended device installation should wait until the condition clears before undergoing treatment.
 
FDA Approves Mylan, Teva Flomax Generics.  Mylan Inc. and Teva Pharmaceutical Industries Ltd. "reported lately that, they are started selling their own versions of Flomax [tamsulosin HCl], a drug that treats enlarged prostate, after getting approval from the Food and Drug Administration." In March, Impax Laboratories also "began selling an authorized generic" due to "an agreement with Boehringer Ingelheim, the company that developed the drug." 
 
Cancer Risk After Kidney Transplant Similar From All Antirejection Drugs. According to a study published in the April 29 issue of the Journal of the American Society of Nephrology, "the type of drug treatment used to prevent organ rejection in kidney transplant patients doesn't affect cancer risk." Researchers arrived at this conclusion after examining "the incidence of cancer in 481 kidney transplant patients" who "had received one of three treatment regimens: azathioprine and prednisolone; cyclosporine monotherapy; or cyclosporine monotherapy followed by a switch to azathioprine and prednisolone after three months," and who were then followed for 20 years after transplant. 
 
Obese Children May Metabolize Common Medications At Different Rates Than Leaner Children.  According to a study presented at the Experimental Biology annual meeting, "children who are obese appear to metabolize common medications at different rates than their leaner counterparts." After "evaluating the metabolism of active ingredients found in an over-the-counter cough syrup and in a soft drink in 16 healthy-weight children and nine obese children," researchers found that "the obese children had slower rates of breakdown of the cough syrup and higher rates for the soft drink compared to the leaner children." 
 
Risk For Low-Dose Aspirin-Associated Peptic Ulcer May Be Higher In Elderly Women.  The risk for low-dose aspirin (LDA)-associated peptic ulcer is higher in elderly women," according to a study in the World Journal of Gastroenterology that included 453 patients who underwent esophagogastroduodenoscopy. They "continued taking LDA during the entire observation period," and LDA-associated peptic ulcer was eventually "diagnosed in 119 patients (87 men and 32 women)." In short, "compared with male patients, female patients had a significantly shorter time to diagnosis of LDA-associated peptic ulcer by endoscopy."  
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement
    To contact Dr. Shruti Bhat text or WhatsApp at 1.403.969.6219

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​Twitter, YouTube, LinkedIn​

© Copyright 1992- 2025 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media